ClinicalTrials.Veeva

Menu
G

Galilee Medical Center | Department of Nephrology and Hypertension

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
LY3298176
Etrasimod
Guselkumab
Daratumumab
Apixaban
Ontamalimab
Prednisone
Doxorubicin
Cyclophosphamide

Parent organization

This site is a part of Galilee Medical Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

35 of 112 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Active, not recruiting
Crohn's Disease
Drug: Mirikizumab

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver).PBC is a slowly progressiv...

Enrolling
Primary Biliary Cholangitis (PBC)
Drug: Elafibranor
Other: Matched 80 mg placebo

The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and ado...

Enrolling
Colitis, Ulcerative
Drug: Icotrokinra
Drug: Placebo

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP)...

Active, not recruiting
Multiple Myeloma
Drug: Talquetamab
Drug: Dexamethasone

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting
FIGO Stage III-IV
Newly Diagnosed
Drug: Placebo Oral Tablet
Drug: Nivolumab

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately t...

Enrolling
Crohn Disease
Drug: Icotrokinra
Drug: Placebo

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabet...

Active, not recruiting
Obesity
Type 2 Diabetes
Drug: Tirzepatide
Drug: Placebo

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in par...

Enrolling
Crohn Disease
Drug: Guselkumab
Drug: JNJ-78934804

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in par...

Enrolling
Colitis, Ulcerative
Drug: JNJ-78934804
Drug: Guselkumab

The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and...

Active, not recruiting
Multiple Sclerosis
Drug: LY3541860
Drug: Placebo

The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus ery...

Enrolling
Lupus Erythematosus, Systemic
Drug: Nipocalimab
Drug: Standard of care treatment

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiova...

Enrolling
Chronic Kidney Disease
Atherosclerosis Cardiovascular Disease
Drug: Orforglipron
Drug: Placebo

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute l...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: revumenib
Drug: cobicistat

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study...

Enrolling
Diffuse Large B-cell Lymphoma (DLBCL)
Drug: Cyclophosphamide
Drug: Odronextamab

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
PBC
Primary Biliary Cholangitis
Drug: Placebo
Drug: Volixibat

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Active, not recruiting
Primary Sclerosing Cholangitis
Drug: Placebo
Drug: Volixibat

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants:* Participants rec...

Enrolling
Beta-thalassemia
Myelodysplastic Syndromes (MDS)
Drug: Luspatercept

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Lilly logo
AbbVie logo
W
Pfizer logo
Shire logo
Takeda logo
Regeneron Pharmaceuticals logo
Roche logo
V

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems